Key facts
- This page summarizes Eric Venker's Form 4 filing for Roivant Sciences Ltd. (ROIV).
- 9 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 27 Jul 2023, 21:30.
Eric Venker - 25 Jul 2023 Form 4 Insider Report for Roivant Sciences Ltd. (ROIV)
- Reporting relationship
- Chief Operating Officer
- Issuer ticker
- ROIV
- Reported as of
- 25 Jul 2023
- Net transaction value
- -$886,506
- SEC form
- 4
- Accepted by SEC
- 27 Jul 2023, 21:30:24 UTC
- Prior SEC filing
- 24 Jul 2023
- Next SEC filing
- 02 Aug 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jo Chen, as Attorney-in-Fact for Eric Venker
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Eric Venker filed Form 4 for Roivant Sciences Ltd. (ROIV) on 27 Jul 2023.
Change
- Previous filing in this sequence was filed on 24 Jul 2023.
- Current net transaction value: -$886,506.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ROIV
transaction
Common Shares
Options Exercise
- Transaction value
- $109,124
- Shares
- +28,344
- Change %
- +4.5%
- Price
- $3.85
- Shares after
- 656,262
- Date
- 25 Jul 2023
- Ownership
- Direct
ROIV
transaction
Common Shares
Sale
- Transaction value
- $307,816
- Shares
- -28,344
- Change %
- -4.3%
- Price
- $10.86
- Shares after
- 627,918
- Date
- 25 Jul 2023
- Ownership
- Direct
- Footnotes
- F1
ROIV
transaction
Common Shares
Options Exercise
- Transaction value
- $283,237
- Shares
- +73,568
- Change %
- +12%
- Price
- $3.85
- Shares after
- 701,486
- Date
- 26 Jul 2023
- Ownership
- Direct
ROIV
transaction
Common Shares
Sale
- Transaction value
- $802,627
- Shares
- -73,568
- Change %
- -10%
- Price
- $10.91
- Shares after
- 627,918
- Date
- 26 Jul 2023
- Ownership
- Direct
- Footnotes
- F1
ROIV
transaction
Common Shares
Options Exercise
- Transaction value
- $90,945
- Shares
- +23,622
- Change %
- +3.8%
- Price
- $3.85
- Shares after
- 651,540
- Date
- 27 Jul 2023
- Ownership
- Direct
ROIV
transaction
Common Shares
Sale
- Transaction value
- $259,370
- Shares
- -23,622
- Change %
- -3.6%
- Price
- $10.98
- Shares after
- 627,918
- Date
- 27 Jul 2023
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ROIV
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -28,344
- Change %
- -0.19%
- Price
- $0.000000
- Shares after
- 14,920,374
- Date
- 25 Jul 2023
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 28,344
- Exercise price
- $3.85
- Footnotes
- F2
ROIV
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -73,568
- Change %
- -0.49%
- Price
- $0.000000
- Shares after
- 14,846,806
- Date
- 26 Jul 2023
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 73,568
- Exercise price
- $3.85
- Footnotes
- F2
ROIV
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -23,622
- Change %
- -0.16%
- Price
- $0.000000
- Shares after
- 14,823,184
- Date
- 27 Jul 2023
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 23,622
- Exercise price
- $3.85
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2023.
Footnote F2
Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).